Colorectal Cancer Screening in Primary Care (COLO-ALERT)

August 29, 2016 updated by: Jordi Gol i Gurina Foundation

Effectiveness of an Electronic Alert Into the Primary Care Medical Health Record to Increase Participation in a Population Colorectal Cancer Screening Program.

The implementation of screening programs for colorectal cancer by screening for fecal occult blood has proven effective in reducing the incidence and mortality from this type of neoplasms. However, to ensure the efficiency of the programs require population participation rates of at least 50%. Experiences in our country show that the population participation is far from this recommended minimum number.

Interventions to promote preventive activities in primary care are well received by the population; in the case of colorectal cancer, direct recommendation of primary care professionals to carry out the screening is one of the factors with greatest impact on increasing population participation in such programs. Care overload, circuit design for screening without the direct intervention of primary care professionals and the multiplicity of tasks that they must face, are elements that influence the low recommendation for screening in the target population who consults for any other reason.

The introduction of specific reminders in electronic medical record (in widespread use in primary care), as a tool to facilitate and encourage direct referral by physicians and nurse practitioners to perform colorectal cancer screening will mean an increase of at least 10% in participation of the target population, increasing the efficiency of screening programs. The introduction of this new software tool will have good acceptance and increase compliance with recommendations from health professionals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background:

Colorectal cancer (CRC) is an important public health problem in our country. Over the last decade, several autonomous regions in Spain have carried out screening programs, but population participation rates remain below recommended European targets.

Reminders on electronic medical record (EMR) have been identified as a low-cost and high-reach strategy to increase participation. The population-based colorectal cancer screening program in the city of Barcelona is aimed at men and women between ages 50 and 69 involving immunochemical fecal occult blood test (iFOBT) every 2 years. Community pharmacies participating in the program are in charge of delivery and collection of iFOBT.

Aims:

Main: To asses the effectiveness of an intervention in primary care, by using reminder systems applied to the electronic medical records to promote the population's participation in a Public CRC Screening Program.

Secondary:

  • To know the population's reasons for refusing to take part in the screening program.
  • To know the health professionals' opinion on the official program implementation.
  • To know the health professionals' opinion on the implementation of the new computerized tool.

Methods:

Design: Randomized controlled trial and a cross-sectional second phase. Setting: 11 primary care centers

Subjects:

Inclusion criteria Patients

  • Men and women, aged between 50-69, with an average risk of developing CRC, involved to participate in the first round of a population-based CRC screening program (N 57.020).
  • To be registered with a primary care physician (PCP) at one of the centers participating.

Health care professionals:

- All the physicians and nurses working at every center voluntarily participating (N 280).

Exclusion criteria Patients: Refusal to participate. Health care professionals: Refusal to participate by the center where they work.

Intervention It consists of entering a reminder in the EMR of patients (e-cap program), in the form of a specific icon, in the medical scheduler, which identifies subjects who had been invited to take part in the CRC screening program. The alert is addressed to physicians and nurses, in order to promote CRC screening, through some brief advice and asking the patient to fill in a data collection sheet specifically designed for this study and also included in the EMR. Health care professionals in the intervention group will have had a training session on the intervention's characteristics and development.

Sample size: The target population registered with the centers involved in the study is about 60.000 people. It is estimated that 90% of them will be invited to participate in the screening program. In case of low participation (30%), the resulting sample could identify a difference of at least 10% between the control group and the intervention group, with an alpha error of 5% and a statistical power of 95%, and an estimated loss to follow up rate at 20 %.

Randomization:The randomization unit is the PCP. The allocation of the participant PCPs to the control or intervention groups is carried out through a stratified random sampling by center, allocating 50% of the physicians to the control or intervention group, respectively.

The nurses are allocated to the intervention/control group according to the study group of the PCP that they share patients care with. Patients are allocated to the intervention/control group according to the study group of their PCP.

Masking: Given the nature of the intervention, there's no masking of the health professionals or of the statistician responsible for the statistical analysis, but due to the objectivity of the final outcome we don't think the result could be influenced by this fact. Moreover the data manager for the CRC screening program, responsible for the data management of the participation outcome, does not know what study group the invited population was allocated to. Patients are also unaware of study group that they have been assigned to, and they have no access to the EMR.

Outcomes:

Primary outcome: CRC screening status (Update, not update, exclusion)

Secondary outcomes:

  • Patient's characteristics: age, gender, socioeconomic deprivation index, risk factor for colorectal cancer, clinical risk group, number of visits.
  • Health professionals characteristics: age, gender, knowledge about CRC screening.
  • Reminder: date when the sheet was filled in, previous participation in the CRC screening program (yes, no and barriers), exclusion criteria (normal colonoscopy within the previous five years, high CRC risk for personal or family history, symptoms of CRC), intention to participate (yes, no and barriers).
  • Health Professionals Opinion questionnaire on:

Population-based CRC screening program: Information given, process operation, primary care professionals implication.

Electronic reminder: usefulness, usage, operation.

Data collection: Data obtained from population based CRC screening program, the EMR and two questionnaires for the cross-sectional second phase.

Statistical analysis: Data will be analyzed using Stata, version 12.1, statistical software package and an intention-to-treat approach will be applied. Analyses will include standard descriptive statistics, Student's t tests, correlation and regression, to examine differences between groups. All tests will be two-tailed and an alpha level of 0.05 will be applied as the criterion for statistical significance.

Limits:

Given the nature of the intervention and the great social, economic and demographical differences of the population registered with the centers participating in this study, we take the physicians as a unit of randomization, instead of the centers or the patients.

External validity: This is an urban population study, but as the EMR is universally used in Catalonia's primary care centers, we don't expect differences due to the area of work.

Ethical aspects:

The investigators are committed to complying with the prevailing norms of Good Clinical Practice, as well as with the requirements of the Declaration of Helsinki and the clauses of general and particular ethical conditions related to the right to privacy, anonymity and confidentiality. Neither the first name nor the surnames or any other type of data indicating the identity of the subjects will be registered. Therefore, identification will be made by numerical codes. Since this type of study is developed in the usual clinical setting, authorization and support must be and has already been granted by the representatives and authorities of the groups involved and thus, individual informed consent is not necessary. However, the consent of target population attending a primary care appointment will be registered in the EMR. The protocol has been approved by the Clinical Investigation Ethics Committee of the Jordi Gol i Gurina Foundation (protocol number P10/31).

Study Type

Interventional

Enrollment (Actual)

41042

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Catalonia
      • Barcelona, Catalonia, Spain, 08007
        • Jordi Gol Foundation
      • Barcelona, Catalonia, Spain, 08007
        • Jordi Gol Gurina Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Patients:

    1. Men and women, aged between 50-69, with an average risk of developing CRC, involved to participate in the first round of a population-based CRC screening program (N=57.020)
    2. To be registered with a primary care physician (PCP) at one of the centers participating.
  • Health care professionals: All the physicians and nurses working at every center voluntarily participating (N=280).

Exclusion criteria

  • Patients: Refusal to participate.
  • Health care professionals: Refusal to participate by the center where they work.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: electronic reminder
Electronic reminder introduced into primary care medical health record.
Behavioral: electronic reminder
Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
No Intervention: Usual care
Usual care control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient's status participation to colorectal cancer screening program
Time Frame: one year

Status of participation at the end of the intervention (1 year):

  1. Update: completion of faecal occult blood test by invitation from the colorectal cancer screening program within the duration of the study.
  2. Exclusion: exclusion criteria identified through the screening process by colorectal cancer screening program.
  3. Not update: No completion of faecal occult blood test.
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jordi Gol i Gurina Foundation

Collaborators

Instituto de Salud Carlos III

Investigators

  • Principal Investigator: Carolina Guiriguet, Catalan Health Institute. IDIAP Jordi Gol
  • Study Chair: Laura Muñoz, IDIAP Jordi Gol
  • Study Chair: Irene Rivero, Catalan Institute of Health
  • Study Chair: Carme Vela, Catalan Institute of Health
  • Study Chair: Mercedes Vilarrubí, Catalan Institute of Health
  • Study Chair: Miquel Torres, Hospital Esperit Sant
  • Study Chair: Jaume Grau, Hospital Clinic Provincial
  • Study Chair: Andrea Buron, Hospital del Mar
  • Study Chair: Cristina Hernández, Hospital del Mar
  • Study Chair: Antonio Fuentes, Catalan Institute of Health
  • Study Chair: Dolores Reina, Catalan Institute of Health
  • Study Chair: Rosa De León, Catalan Institute of Health
  • Study Chair: Leonardo Mendez, Catalan Health Institute. IDIAP Jordi Gol
  • Study Chair: Pere Toran, Catalan Health Institute. IDIAP Jordi Gol

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (Actual)

March 1, 2013

Study Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

June 2, 2013

First Submitted That Met QC Criteria

June 11, 2013

First Posted (Estimate)

June 13, 2013

Study Record Updates

Last Update Posted (Estimate)

August 30, 2016

Last Update Submitted That Met QC Criteria

August 29, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PI10/01994

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colorectal Neoplasms

Clinical Trials on electronic reminder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe